Jazz Pharmaceuticals Plc - Understand $jazz stock

$JAZZ Market Cap: $7.513 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$3.993B

TTM

Gross Margin

89.38%

TTM

Net Earnings

$463.2M

TTM

Current Assets

$4.390B

Q3 2024

Current Liabilities

$1.030B

Q3 2024

Current Ratio

426.26%

Q3 2024

Total Assets

$12.26B

Q3 2024

Total Liabilities

$7.222B

Q3 2024

Book Value

$5.034B

Q3 2024

Cash

$2.218B

Q3 2024

P/E

16.22

Nov 14, 2024 EST

Free Cash Flow

$1.112B

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Revenue	$3.834B	$3.659B	$3.094B	$2.364B	$2.162B	$1.891B	$1.619B	$1.488B	$1.325B	$1.173B	$872.4M	$586.0M	$272.3M	$173.8M	$128.4M	$67.50M	$65.30M	$44.90M	$21.40M	$0.00
YoY Change	4.78%	18.26%	30.91%	9.34%	14.32%	16.82%	8.79%	12.32%	12.95%	34.44%	48.88%	115.21%	56.68%	35.34%	90.22%	3.37%	45.43%	109.81%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Revenue	$3.834B	$3.659B	$3.094B	$2.364B	$2.162B	$1.891B	$1.619B	$1.488B	$1.325B	$1.173B	$872.4M	$586.0M	$272.3M	$173.8M	$128.4M	$67.50M	$65.30M	$44.90M	$21.40M	$0.00
Cost Of Revenue	$435.6M	$540.5M	$440.8M	$148.9M	$127.9M	$121.5M	$110.2M	$105.4M	$102.5M	$117.4M	$102.1M	$78.40M	$13.90M	$13.60M	$9.600M	$13.90M	$8.900M	$7.000M	$4.300M	$0.00
Gross Profit	$3.399B	$3.119B	$2.653B	$2.215B	$2.034B	$1.769B	$1.509B	$1.383B	$1.222B	$1.056B	$770.3M	$507.6M	$258.3M	$160.2M	$118.8M	$53.60M	$56.40M	$37.90M	$17.10M	$0.00
Gross Profit Margin	88.64%	85.23%	85.76%	93.7%	94.08%	93.57%	93.19%	92.92%	92.26%	89.99%	88.29%	86.62%	94.87%	92.18%	92.52%	79.41%	86.37%	84.41%	79.91%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Selling, General & Admin	$1.343B	$1.417B	$1.452B	$854.2M	$736.9M	$683.5M	$544.2M	$502.9M	$449.1M	$406.1M	$304.3M	$223.9M	$108.9M	$69.00M	$58.70M	$111.4M	$78.50M	$51.40M	$23.60M	$7.500M
YoY Change	-5.21%	-2.39%	69.94%	15.92%	7.81%	25.61%	8.21%	11.97%	10.59%	33.46%	35.92%	105.52%	57.89%	17.54%	-47.31%	41.91%	52.72%	117.8%	214.67%
% of Gross Profit	39.52%	45.43%	54.71%	38.57%	36.23%	38.63%	36.07%	36.37%	36.74%	38.48%	39.5%	44.11%	42.17%	43.07%	49.41%	207.84%	139.18%	135.62%	138.01%
Research & Development	$849.7M	$590.5M	$505.7M	$335.4M	$299.7M	$226.6M	$198.4M	$162.3M	$135.3M	$85.18M	$41.63M	$20.48M	$14.12M	$25.61M	$36.60M	$70.00M	$69.80M	$55.00M	$45.80M	$18.00M
YoY Change	43.9%	16.75%	50.8%	11.89%	32.26%	14.2%	22.27%	20.0%	58.78%	104.6%	103.31%	45.02%	-44.87%	-30.02%	-47.71%	0.29%	26.91%	20.09%	154.44%
% of Gross Profit	25.0%	18.93%	19.06%	15.14%	14.74%	12.81%	13.15%	11.74%	11.07%	8.07%	5.4%	4.03%	5.47%	15.99%	30.81%	130.6%	123.76%	145.12%	267.84%
Depreciation & Amortization	$30.40M	$30.30M	$26.70M	$18.70M	$15.30M	$15.20M	$13.10M	$11.80M	$9.900M	$7.097M	$3.048M	$1.307M	$379.0K	$886.0K	$9.100M	$15.00M	$10.50M	$10.30M	$5.500M	$100.0K
YoY Change	0.33%	13.48%	42.78%	22.22%	0.66%	16.03%	11.02%	19.19%	39.5%	132.84%	133.21%	244.85%	-57.22%	-90.26%	-39.33%	42.86%	1.94%	87.27%	5400.0%
% of Gross Profit	0.89%	0.97%	1.01%	0.84%	0.75%	0.86%	0.87%	0.85%	0.81%	0.67%	0.4%	0.26%	0.15%	0.55%	7.66%	27.99%	18.62%	27.18%	32.16%
Operating Expenses	$2.193B	$2.007B	$1.957B	$1.190B	$1.037B	$1.276B	$1.090B	$896.3M	$816.6M	$977.3M	$532.1M	$388.1M	$144.4M	$116.0M	$102.9M	$194.2M	$157.6M	$115.9M	$74.30M	$25.40M
YoY Change	9.23%	2.55%	64.54%	14.75%	-18.76%	17.09%	21.59%	9.76%	-16.44%	83.66%	37.09%	168.71%	24.53%	12.72%	-47.01%	23.22%	35.98%	55.99%	192.52%
Operating Profit	$578.6M	-$65.53M	$170.3M	$378.1M	$532.4M	$614.8M	$528.8M	$591.7M	$508.2M	$195.6M	$340.3M	$197.8M	$127.8M	$57.79M	$15.90M	-$140.6M	-$101.2M	-$78.00M	-$57.20M	-$25.40M
YoY Change	-982.95%	-138.48%	-54.96%	-28.98%	-13.41%	16.26%	-10.62%	16.42%	159.84%	-42.53%	72.01%	54.77%	121.2%	263.45%	-111.31%	38.93%	29.74%	36.36%	125.2%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Interest Expense	-$289.4M	-$288.2M	-$278.8M	-$99.71M	-$72.26M	-$78.50M	-$77.76M	-$61.94M	-$56.92M	-$52.71M	-$26.92M	-$16.87M	-$1.600M	-$12.72M	-$22.80M	-$17.90M	-$7.700M	-$11.80M	-$5.800M	$600.0K
YoY Change	0.41%	3.4%	179.59%	37.98%	-7.95%	0.96%	25.53%	8.83%	7.98%	95.84%	59.56%	954.31%	-87.43%	-44.19%	27.37%	132.47%	-34.75%	103.45%	-1066.67%
% of Operating Profit	-50.03%		-163.71%	-26.37%	-13.57%	-12.77%	-14.7%	-10.47%	-11.2%	-26.95%	-7.91%	-8.53%	-1.25%	-22.02%	-143.4%
Other Income/Expense, Net									$1.445M	$8.683M	-$1.697M			$0.00	$0.00	$0.00	$1.800M	-$1.100M	-$900.0K	$0.00
YoY Change									-83.36%	-611.67%						-100.0%	-263.64%	22.22%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Pretax Income	$449.2M	-$50.31M	$97.56M	-$102.3M	-$6.451M	$170.7M	$77.48M	$179.6M	$435.9M	$151.6M	$308.0M	$177.4M	$125.0M	$32.78M	-$6.800M	-$184.3M	-$138.8M	-$59.40M	-$85.20M	-$24.80M
YoY Change	-992.87%	-151.57%	-195.34%	1486.23%	-103.78%	120.28%	-56.85%	-58.81%	187.64%	-50.79%	73.63%	41.9%	281.3%	-582.03%	-96.31%	32.78%	133.67%	-30.28%	243.55%
Income Tax	-$119.9M	-$158.6M	$216.1M	$33.50M	-$73.20M	$80.20M	-$47.70M	$135.2M	$106.4M	$94.23M	$91.64M	-$83.79M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income	-26.69%		221.51%			46.99%	-61.57%	75.31%	24.41%	62.18%	29.76%	-47.25%	0.0%	0.0%
Net Earnings	$414.8M	-$224.1M	-$329.7M	$238.6M	$523.4M	$447.1M	$487.8M	$396.8M	$329.5M	$58.39M	$216.3M	$288.6M	$125.0M	$32.78M	-$6.800M	-$184.3M	-$138.8M	-$59.40M	-$85.20M	-$24.80M
YoY Change	-285.14%	-32.03%	-238.16%	-54.41%	17.06%	-8.35%	22.94%	20.42%	464.4%	-73.01%	-25.04%	130.9%	281.3%	-582.03%	-96.31%	32.78%	133.67%	-30.28%	243.55%
Net Earnings / Revenue	10.82%	-6.12%	-10.65%	10.1%	24.21%	23.64%	30.14%	26.67%	24.87%	4.98%	24.79%	49.25%	45.9%	18.86%	-5.3%	-273.04%	-212.56%	-132.29%	-398.13%
Basic Earnings Per Share	$6.55	-$3.58	-$5.52	$4.28	$9.22	$7.45	$8.13	$6.56	$5.38	$0.98	$3.71	$5.09	$3.01	$0.90
Diluted Earnings Per Share	$6.10	-$3.58	-$5.52	$4.22	$9.09	$7.30	$7.96	$6.41	$5.23	$0.93	$3.51	$4.79	$2.67	$0.83	-$226.7K	-$7.199M	-$10.06M	-$2.415M	-$3.463M	-$1.008M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Cash & Short-Term Investments	$1.626B	$881.5M	$591.4M	$2.133B	$1.077B	$824.6M	$601.0M	$426.0M	$988.8M	$684.0M	$636.5M	$387.2M	$157.9M	$44.80M	$15.60M	$25.90M	$102.9M	$78.90M	$20.60M
YoY Change	84.5%	49.04%	-72.27%	97.98%	30.65%	37.2%	41.08%	-56.92%	44.56%	7.46%	64.39%	145.22%	252.46%	187.18%	-39.77%	-74.83%	30.42%	283.01%
Cash & Equivalents	$1.069B	$517.5M					$386.0M	$366.0M	$988.8M	$684.0M	$636.5M	$387.2M	$82.10M	$44.80M	$15.60M	$24.90M	$102.9M	$78.90M	$20.60M
Short-Term Investments	$120.0M	$30.00M	$80.70M	$1.616B	$744.2M	$609.0M	$215.0M	$60.00M	$0.00			$0.00	$75.80M	$0.00		$1.000M	$0.00
Other Short-Term Assets	$357.0M	$268.0M	$383.8M	$214.9M	$118.3M	$92.60M	$99.90M	$53.80M	$39.70M	$115.4M	$74.70M	$62.30M	$3.000M	$2.600M	$5.700M	$7.200M	$5.500M	$4.200M	$3.900M
YoY Change	33.22%	-30.18%	78.6%	81.66%	27.75%	-7.31%	85.69%	35.52%	-65.6%	54.48%	19.9%	1976.67%	15.38%	-54.39%	-20.83%	30.91%	30.95%	7.69%
Inventory	$597.0M	$714.1M	$1.073B	$95.40M	$78.60M	$53.00M	$43.20M	$34.10M	$19.50M	$30.00M	$28.70M	$26.50M	$3.900M	$5.000M	$3.400M	$4.300M	$2.200M	$3.000M	$3.300M
Prepaid Expenses
Receivables	$705.8M	$651.5M	$563.4M	$396.5M	$356.0M	$263.8M	$224.1M	$234.2M	$209.7M	$186.4M	$124.8M	$75.50M	$34.40M	$22.10M	$12.30M	$6.600M	$5.400M	$5.400M	$3.600M
Other Receivables	$149.3M	$91.13M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.435B	$2.606B	$2.611B	$2.840B	$1.630B	$1.234B	$968.3M	$748.1M	$1.258B	$1.016B	$864.6M	$551.6M	$199.1M	$74.50M	$37.00M	$44.00M	$116.1M	$91.60M	$31.40M
YoY Change	31.82%	-0.2%	-8.04%	74.18%	32.12%	27.44%	29.43%	-40.52%	23.81%	17.49%	56.74%	177.05%	167.25%	101.35%	-15.91%	-62.1%	26.75%	191.72%
Property, Plant & Equipment	$235.0M	$301.4M	$343.4M	$257.1M	$270.9M	$200.4M	$170.1M	$107.5M	$85.60M	$58.40M	$14.20M	$7.300M	$1.600M	$700.0K	$1.100M	$2.500M	$3.900M	$2.100M	$1.900M
YoY Change	-22.03%	-12.24%	33.58%	-5.09%	35.18%	17.81%	58.23%	25.58%	46.58%	311.27%	94.52%	356.25%	128.57%	-36.36%	-56.0%	-35.9%	85.71%	10.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$551.8M	$440.6M	$363.9M	$285.9M	$276.7M	$110.2M	$58.70M	$38.90M	$146.6M	$124.6M	$96.50M	$95.10M	$100.0K	$300.0K	$1.200M	$200.0K	$13.30M	$13.50M	$13.80M
YoY Change	25.22%	21.07%	27.3%	3.32%	151.09%	87.73%	50.9%	-73.47%	17.66%	29.12%	1.47%	95000.0%	-66.67%	-75.0%	500.0%	-98.5%	-1.48%	-2.17%
Total Long-Term Assets	$7.958B	$8.229B	$9.687B	$3.696B	$3.909B	$3.970B	$4.155B	$4.052B	$2.075B	$2.323B	$1.374B	$1.415B	$54.50M	$61.20M	$70.40M	$73.50M	$91.50M	$123.0M	$133.4M
YoY Change	-3.3%	-15.05%	162.08%	-5.43%	-1.53%	-4.47%	2.55%	95.29%	-10.69%	69.13%	-2.92%	2496.15%	-10.95%	-13.07%	-4.22%	-19.67%	-25.61%	-7.8%
Total Assets	$11.39B	$10.84B	$12.30B	$6.536B	$5.539B	$5.204B	$5.124B	$4.800B	$3.333B	$3.339B	$2.238B	$1.967B	$253.6M	$135.7M	$107.4M	$117.5M	$207.6M	$214.6M	$164.8M
YoY Change
Accounts Payable	$102.8M	$90.76M	$100.3M	$26.90M	$47.50M	$40.60M	$24.40M	$22.40M	$21.80M	$25.10M	$21.00M	$15.90M	$5.100M	$3.000M	$2.200M	$5.700M	$2.900M	$5.400M	$4.800M
YoY Change	13.21%	-9.51%	272.86%	-43.37%	17.0%	66.39%	8.93%	2.75%	-13.15%	19.52%	32.08%	211.76%	70.0%	36.36%	-61.4%	96.55%	-46.3%	12.5%
Accrued Expenses	$792.8M	$802.9M	$647.5M	$349.1M	$266.8M	$263.4M	$198.8M	$193.3M	$164.1M	$164.1M	$119.7M	$104.7M	$19.90M	$13.40M	$12.00M	$16.30M	$29.00M	$12.90M	$11.10M
YoY Change	-1.25%	24.0%	85.47%	30.85%	1.29%	32.49%	2.85%	17.79%	0.0%	37.09%	14.33%	426.13%	48.51%	11.67%	-26.38%	-43.79%	124.81%	16.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$7.400M	$9.400M	$3.900M	$3.500M	$2.200M	$0.00
YoY Change													-100.0%	-21.28%	141.03%	11.43%	59.09%
Long-Term Debt Due	$605.4M	$31.38M	$31.41M	$246.3M	$33.40M	$33.40M	$40.60M	$36.10M	$37.60M	$9.400M	$5.600M	$29.70M	$0.00	$16.10M	$23.80M	$118.5M	$0.00
YoY Change	1829.14%	-0.08%	-87.25%	637.43%	0.0%	-17.73%	12.47%	-3.99%	300.0%	67.86%	-81.14%		-100.0%	-32.35%	-79.92%
Total Short-Term Liabilities	$1.537B	$933.2M	$809.3M	$653.7M	$364.5M	$345.5M	$293.9M	$257.4M	$226.6M	$216.8M	$204.0M	$191.5M	$52.90M	$59.90M	$59.20M	$173.5M	$36.90M	$30.50M	$23.30M
YoY Change	64.67%	15.31%	23.8%	79.34%	5.5%	17.56%	14.18%	13.59%	4.52%	6.27%	6.53%	262.0%	-11.69%	1.18%	-65.88%	370.19%	20.98%	30.9%
Long-Term Debt	$5.113B	$5.699B	$6.025B	$1.849B	$1.574B	$1.563B	$1.540B	$1.994B	$1.151B	$1.333B	$544.4M	$427.1M	$0.00	$24.60M	$91.10M	$0.00	$75.10M	$74.30M	$89.10M
YoY Change	-10.27%	-5.42%	225.95%	17.45%	0.7%	1.47%	-22.73%	73.21%	-13.66%	144.86%	27.46%		-100.0%	-73.0%		-100.0%	1.08%	-16.61%
Other Long-Term Liabilities	$158.9M	$173.4M	$198.4M	$243.5M	$265.5M	$228.5M	$192.7M	$115.2M	$73.00M	$42.90M	$25.80M	$48.20M	$7.900M	$20.60M	$29.90M	$24.40M	$27.30M	$14.00M	$800.0K
YoY Change	-8.36%	-12.58%	-18.52%	-8.29%	16.19%	18.58%	67.27%	57.81%	70.16%	66.28%	-46.47%	510.13%	-61.65%	-31.1%	22.54%	-10.62%	95.0%	1650.0%
Total Long-Term Liabilities	$5.272B	$5.872B	$6.224B	$2.092B	$1.839B	$1.792B	$1.733B	$2.109B	$1.224B	$1.376B	$570.2M	$475.3M	$7.900M	$45.20M	$121.0M	$24.40M	$102.4M	$88.30M	$89.90M
YoY Change	-10.22%	-5.65%	197.5%	13.73%	2.67%	3.37%	-17.81%	72.29%	-11.05%	141.3%	19.97%	5916.46%	-82.52%	-62.64%	395.9%	-76.17%	15.97%	-1.78%
Total Liabilities	$7.656B	$7.750B	$8.333B	$2.876B	$2.428B	$2.446B	$2.411B	$2.923B	$1.734B	$1.968B	$942.7M	$845.2M	$60.80M	$105.2M	$180.2M	$197.9M	$139.3M	$118.8M	$113.2M
YoY Change	-1.2%	-7.01%	189.74%	18.46%	-0.74%	1.47%	-17.53%	68.56%	-11.88%	108.74%	11.54%	1290.13%	-42.21%	-41.62%	-8.94%	42.07%	17.26%	4.95%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Basic Shares Outstanding	63.29M shares	62.54M shares	59.69M shares	55.71M shares	56.75M shares	59.98M shares	60.02M shares	60.50M shares	61.23M shares	59.75M shares	58.30M shares	56.64M shares	41.50M shares	36.34M shares
Diluted Shares Outstanding	72.07M shares	62.54M shares	59.69M shares	56.52M shares	57.55M shares	61.22M shares	61.32M shares	61.87M shares	63.04M shares	62.61M shares	61.57M shares	60.20M shares	46.80M shares	39.41M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $7.5127 Billion

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The firm is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Industry: Pharmaceutical Preparations Peers: Avadel Pharmaceuticals PLC Endo International plc GH Research PLC Iterum Therapeutics PLC Mallinckrodt plc Nabriva Therapeutics plc Perrigo Company PLC